Study treatment for relapsed or hard-to-treat AML
Part of Blood & lymphatic, Cancer clinical trials.
This Phase 2 trial tests a new combination treatment (the “CAV regimen”) for people with relapsed or refractory acute myeloid leukemia (AML). It may help your body control leukemia again, especially if prior standard intensive treatments were not enough or the leukemia came back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 16 to 70 and have been diagnosed with relapsed or refractory AML.
- Your leukemia must fit either “didn’t respond” after at least two induction treatments, or “came back” after prior remission (including signs in blood, bone marrow, or outside the bone marrow).
- Your daily functioning is fairly good (ECOG score less than 2).
- You have expected survival of at least 12 weeks and you can give informed consent.
- Your heart, lungs, liver, and kidneys must be healthy enough for the study (no serious problems).
- You must not have certain exclusions like pregnancy/breastfeeding without effective birth control, active infection or bleeding, major recent blood clots or brain bleeding, or major heart rhythm problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 trial tests a combination of medicines (decitabine/cedazuridine, venetoclax, and ivosidenib or enasidenib) in people with acute myeloid leukemia (AML) that has come back or hasn’t responded. It may help control the leukemia by targeting cancer cells and specific genetic changes in the leukemia.
This Phase 2 trial tests a combination treatment to try to get rid of remaining cancer cells in young adults whose acute myeloid leukemia (AML) is in remission but still detectable at low levels. It may help patients eliminate “minimal residual disease” (small traces of leukemia cells) and reduce relapse risk.
This trial compares two types of chemotherapy for people with acute myeloid leukemia (AML) that came back or did not get better after initial treatment. Your doctor will help decide if you can join, and you will be randomly assigned to either a lower-intensity or a higher-intensity treatment plan.
This trial tests a new drug called HC-7366 for people whose acute myeloid leukemia (AML) has come back or hasn't responded to treatment. It aims to see if this drug is safe and helpful when standard options are no longer working.
This Phase 2 trial tests a combination of venetoclax, cladribine, low-dose cytarabine, and azacitidine in people with untreated acute myeloid leukemia (AML). It may help shrink the leukemia and improve blood counts by trying a stronger, multi-drug approach.
This trial tests a combination of chemotherapy drugs (venetoclax, cladribine, cytarabine, and azacitidine) for people newly diagnosed with specific types of acute myeloid leukemia (AML) who cannot have or choose not to have standard intensive chemotherapy.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.